Patients’ profile at study inclusion and clinical findings at autologous hematopoietic stem cell transplantation (HSCT).
| Patients Treated with CD34-HSCT | Patients treated with Unselected-HSCT | Mean ± SD | p | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | CD34 | Untreated | ||
| Age, yrs | 57 | 19 | 54 | 48 | 52 | 43 | 19 | 42 | 30 | 28 | 46.0 ± 15.4 | 32.4 ± 10.1 | 0.094 |
| Sex, female:male | M | F | F | F | M | M | F | F | F | F | 3:2 | 4:1 | 1.000 |
| mRTSS, 0–51 | 38 | 28 | 25 | 15 | 32 | 32 | 17 | 26 | 23 | 20 | 27.6 ± 8.6 | 23.6 ± 5.8 | 0.402 |
| Disease duration, mo | 21 | 31 | 21 | 12 | 36 | 16 | 24 | 18 | 8 | 12 | 24.2 ± 9.4 | 15.6 ±6.1 | 0.141 |
| Interstitial pneumonia | — | — | + | — | + | — | + | — | — | — | — | — | — |
| GFR, ml/min | 76.53 | 121.43 | 101.43 | 114.39 | 99.32 | 139.29 | 120.3 | 101.8 | 82.62 | 103.42 | 102.6 ± 17.2 | 109.5 ± 21.3 | 0.465 |
| DLCO % | 83 | 66.8 | 52.2 | 90.9 | 83.8 | 92.5 | 54.7 | 113.4 | 48 | 94.4 | 75.3 ± 15.7 | 80.6 ± 28.0 | 0.465 |
| γ-globulin, % | 19.5 | 24.7 | 24.1 | 16.8 | 12.5 | 20.5 | 19.8 | — | 16.8 | 16.7 | 19.5 ± 5.1 | 18.5 ± 2.0 | 0.712 |
| Anti-Scl 70, index | <5 | 92.3 | 204.6 | 8.7 | 158.6 | 16.1 | 128.2 | <5 | <5 | 202 | 92.8 ± 90.2 | 69.3 ± 91.5 | 0.597 |
| Prior therapies | PG | PG, D, PSL | PG, PSL | PG, PSL | D, PSL | PG | PG | D, PSL | D, PSL | PG | — | — | — |
| Mobilization | G | G +CYC | G+CYC | G+CYC | G+CYC | G+CYC | G+CYC | G+CYC | G+CYC | G+CYC | — | — | — |
| Conditioning | CYC | CYC | CYC | CYC | CYC | CYC | CYC | CYC | CYC | CYC | — | — | — |
| Infused CD34+ cells, × 106/kg | 2.96 | 5.21 | 2.75 | 3.14 | 12.7 | 3.95 | 2.77 | 4.28 | 14.9 | 2.81 | 5.4 ± 4.2 | 5.7 ± 5.2 | 0.917 |
| Purity, % | 96 | 95 | 90 | 93.53 | 96.59 | — | — | — | — | — | 94.2 ± 2.6 | — | — |
| Neutrophils > 0.5 × 109/l (day) | 11 | 9 | 11 | 9 | 9 | 8 | 11 | 10 | 10 | 10 | 9.8 ± 1.1 | 9.8 ± 1.1 | 0.914 |
| Platelets > 50 × 109/l (day) | 15 | 21 | 16 | 8 | 11 | 0 | 8 | 11 | 11 | 12 | 14.2 ± 5.0 | 8.4 ± 4.9 | 0.138 |
| Transplant related complications | CMV | CMV, HPS | CMV, HC, ES | — | — | — | ES | — | — | — | — | — | — |
mRTSS: modified Rodnan total thickness skin score; PG: prostaglandin derivatives; D: d-penicillamine; PSL: prednisolone; G: granulocyte-colony-stimulating factor; CYC: cyclophosphamide; CMV: cytomegalovirus antigenemia; HPS: hemophagocytic syndrome; HC: hemorrhagic cystitis; ES: engraftment syndrome; GFR: glomerular filtration rate; DLCO: diffusion capacity for carbon monoxide.